A new drug for preventing and treating both deep vein thrombosis and pulmonary embolism has been approved.
The European Commission has today approved apixaban (Eliquis) for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults.
The European Commission approval applies to all European Union member states, as well as Iceland and Norway.
It broadens the clinical use for apixaban, which is already approved for the prevention of venous thromboembolism in adults who have undergone elective total hip or knee replacement surgery, and the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.
The drug has been jointly developed by Bristol-Myers Squibb and Pfizer.